• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    10/10/23 1:31:12 PM ET
    $AKRO
    $ATHX
    $CTCX
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKRO alert in real time by email

    Gainers

    • Inovio Pharmaceuticals (NASDAQ:INO) shares moved upwards by 33.2% to $0.48 during Tuesday's regular session. The current volume of 13.0 million shares is 535.8% of Inovio Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $128.2 million.
    • NanoString Technologies (NASDAQ:NSTG) stock moved upwards by 26.74% to $1.52. Trading volume for this security as of 13:30 EST is 3.2 million, which is 213.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $72.3 million.
    • Scinai Immunotherapeutics (NASDAQ:SCNI) shares increased by 21.21% to $0.8. The company's market cap stands at $3.7 million.
    • Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 20.43% to $3.89. The company's market cap stands at $9.3 million.
    • Carmell Therapeutics (NASDAQ:CTCX) stock rose 17.7% to $3.39. The market value of their outstanding shares is at $78.2 million.
    • Vicarious Surgical (NYSE:RBOT) stock moved upwards by 17.08% to $0.51. Trading volume for Vicarious Surgical's stock is 303.0K as of 13:30 EST. This is 29.7% of its average full-day volume over the last 100 days. The company's market cap stands at $87.0 million.

    Losers

    • Akero Therapeutics (NASDAQ:AKRO) shares decreased by 63.9% to $17.55 during Tuesday's regular session. Akero Therapeutics's stock is trading at a volume of 21.2 million shares as of 13:30 EST. This is 2889.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $975.5 million.
    • Athersys (NASDAQ:ATHX) shares decreased by 49.77% to $0.15. Trading volume for this security as of 13:30 EST is 13.6 million, which is 3014.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.0 million.
    • 89bio (NASDAQ:ETNB) shares fell 35.65% to $9.99. 89bio's stock is trading at a volume of 8.2 million shares as of 13:30 EST. This is 848.3% of its average full-day volume over the last 100 days. The company's market cap stands at $754.4 million.
    • Ventyx Biosciences (NASDAQ:VTYX) stock declined by 23.44% to $22.97. The current volume of 2.8 million shares is 510.9% of Ventyx Biosciences's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $1.3 billion.
    • Protagenic Therapeutics (NASDAQ:PTIX) shares fell 23.27% to $0.89. As of 13:30 EST, this security is trading at a volume of 74.6K shares, making up 801.5% of its average full-day volume over the last 100 days. The company's market cap stands at $3.8 million.
    • Nuwellis (NASDAQ:NUWE) shares decreased by 18.55% to $1.01. The current volume of 321.4K shares is 303.5% of Nuwellis's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $1.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKRO
    $ATHX
    $CTCX
    $CYCN

    CompanyDatePrice TargetRatingAnalyst
    Ventyx Biosciences Inc.
    $VTYX
    11/5/2025$18.00Neutral → Buy
    H.C. Wainwright
    89bio Inc.
    $ETNB
    9/4/2025$32.00Buy
    H.C. Wainwright
    Akero Therapeutics Inc.
    $AKRO
    9/4/2025$72.00Buy
    H.C. Wainwright
    Akero Therapeutics Inc.
    $AKRO
    8/4/2025$76.00Buy
    TD Cowen
    Inovio Pharmaceuticals Inc.
    $INO
    7/9/2025$5.00Overweight
    Piper Sandler
    89bio Inc.
    $ETNB
    3/14/2025$11.00Neutral
    Goldman
    89bio Inc.
    $ETNB
    3/13/2025$25.00Buy
    Citigroup
    89bio Inc.
    $ETNB
    2/4/2025Outperform
    Wolfe Research
    More analyst ratings

    $AKRO
    $ATHX
    $CTCX
    $CYCN
    SEC Filings

    View All

    SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.

    6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

    3/19/26 10:08:08 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nuwellis Inc. filed SEC Form 8-K: Other Events

    8-K - Nuwellis, Inc. (0001506492) (Filer)

    3/17/26 9:13:10 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 15-12G filed by Ventyx Biosciences Inc.

    15-12G - Ventyx Biosciences, Inc. (0001851194) (Filer)

    3/16/26 12:48:18 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $ATHX
    $CTCX
    $CYCN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

    JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, and the owner of Scinai Biopharma Services Ltd., a rapidly expanding contract development and manufacturing organization (CDMO) serving biotechnology and pharmaceutical companies, today announced its participation in BIO-Europe Spring® 2026, taking place March 23–25 in Lisbon, Portugal. This will be Scinai's first major international conference following its recent acquisition of Recipharm Israel and strategic collaboration with Recipharm, marking a significant expansion of its development and manufact

    3/19/26 7:50:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nuwellis Completes Acquisition of Rendiatech

    MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the completion of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients. Rendiatech has no commercial operations and was formed to acquire certain assets of RenalSense Ltd. following its bankruptcy proceedings; the Company purchased Rendiatech primarily to gain access to such assets. The purchase expands Nuwellis' capabilities across the card

    3/17/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

    JERUSALEM, March 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from the Nasdaq Listing Qualifications Department on March 12, 2026 indicating that the Company is not in compliance with the Nasdaq Capital Market's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the American Depositary Shares ("ADSs") was below $1.00 per share for 30 consecutive business days. The notification has no immediate effect on the listing or trading of the ADSs on the Nasdaq Capital Market.In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has

    3/16/26 4:05:00 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKRO
    $ATHX
    $CTCX
    $CYCN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ventyx Biosciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Ventyx Biosciences from Neutral to Buy and set a new price target of $18.00

    11/5/25 7:25:28 AM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Akero Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Akero Therapeutics with a rating of Buy and set a new price target of $72.00

    9/4/25 8:59:48 AM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on 89bio with a new price target

    H.C. Wainwright resumed coverage of 89bio with a rating of Buy and set a new price target of $32.00

    9/4/25 8:59:48 AM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $ATHX
    $CTCX
    $CYCN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Graham G. Walmsley bought $8,787,921 worth of shares (200,000 units at $43.94) (SEC Form 4)

    4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

    3/27/25 7:42:13 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Graham G. Walmsley bought $9,600,000 worth of shares (200,000 units at $48.00) (SEC Form 4)

    4 - Akero Therapeutics, Inc. (0001744659) (Issuer)

    2/7/25 7:54:28 PM ET
    $AKRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $49,999,994 worth of shares (5,714,285 units at $8.75) (SEC Form 4)

    4 - 89bio, Inc. (0001785173) (Issuer)

    2/3/25 5:38:09 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $ATHX
    $CTCX
    $CYCN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Emerson Martin J

    3 - Nuwellis, Inc. (0001506492) (Issuer)

    3/18/26 4:26:10 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by Scinai Immunotherapeutics Ltd.

    3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

    3/18/26 10:08:31 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by Scinai Immunotherapeutics Ltd.

    3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

    3/18/26 10:06:28 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKRO
    $ATHX
    $CTCX
    $CYCN
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

    –Received Positive Pre-Investigational New Drug ("IND") Written Feedback from the U.S. Food and Drug Administration ("FDA")– –Clinical Advisory Board ("CAB") Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept ("POC") Study in Treatment Resistant Depression ("TRD") in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) ("Cyclerion" or "Company"), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced it has received positive written regulatory feedback and responses from the FDA on CYC-126

    2/17/26 7:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKRO
    $ATHX
    $CTCX
    $CYCN
    Financials

    Live finance-specific insights

    View All

    INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP) by the U.S. Food and Drug Administration (FDA); target Prescription Drug User Fee Act (PDUFA) date October 30, 2026 INO-3107 immunological and long-term clinical and safety data published in Nature Communications and The Laryngoscope Advanced promising next-generation DNA medicine technology:Phase 1 proof-of-concept trial of DNA-encoded Monoclonal Antibodies (DMAbs) published in Nature MedicinePromising preclinical data on novel DNA-encoded protein (DPROT) technology presented at the World Federation of

    3/12/26 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    PLYMOUTH MEETING, Pa., March 5, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its fourth quarter and full year 2025 financial results will be released after the market close on March 12, 2026. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. The live webcast will be available

    3/5/26 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $AKRO
    $ATHX
    $CTCX
    $CYCN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Carmell Corporation

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    12/6/24 4:16:05 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by 89bio Inc.

    SC 13D/A - 89bio, Inc. (0001785173) (Subject)

    11/18/24 8:19:11 PM ET
    $ETNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 7:54:08 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care